INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset [Yahoo! Finance]
Insmed, Inc. (INSM)
Last insmed, inc. earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
This phase IIb study, called BiRCh, failed to achieve either its primary or secondary efficacy endpoints. Although the drug was well-tolerated in patients, the results did not show any treatment benefit in patients compared with placebo, even at the highest dose level. Based on this outcome, Insmed decided to end development of Brinsupri in CRSsNP. This announcement surprised investors, who had been expecting positive results from the BiRCh study. Insmed had achieved a significant milestone with Brinsupri in August, when the FDA approved it as the first treatment for non-cystic fibrosis (non-CF) bronchiectasis. Post this approval, it became the second marketed product in Insmed's portfolio after Arikayce (approved to treat a rare lung disease infection). Early commercial traction for Brinsupri has been encouraging — the drug generated $28 million in third-quarter 2025 sales despite receiving approval only in the middle of the quarter, reflecting strong initial uptake. Investors h
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed, Inc. news events
Weekly update
A roundup of the hottest topics
INSM
News
- Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news [CNBC]CNBC
- Insmed (NASDAQ:INSM) had its price target lowered by analysts at TD Cowen from $269.00 to $241.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says [Yahoo! Finance]Yahoo! Finance
- Insmed's ‘win streak' ends as top drug fails study in chronic nasal condition [Yahoo! Finance]Yahoo! Finance
- Insmed (NASDAQ:INSM) was given a new $230.00 price target on by analysts at HC Wainwright.MarketBeat
INSM
Earnings
- 10/30/25 - Miss
INSM
Sec Filings
- 12/18/25 - Form 144
- 12/17/25 - Form 8-K
- 12/9/25 - Form 4
- INSM's page on the SEC website